Calidi Biotherapeutics, Inc. (NYSE: CLDI) shares experienced a notable increase on the stock charts following the announcement of a new patent award. As of the most recent session, CLDI stock saw an 11.05% rise, reaching $1.81 per share.
Strengthening Intellectual Property Portfolio
A new patent has been granted to Calidi Biotherapeutics for their revolutionary SuperNova technology. This development significantly strengthens CLDI’s intellectual property portfolio and will position the business to progress its CLD-201 product toward clinical trials.
Top 5 Artificial Intelligence Stocks to Buy for 2024
By now, you're well aware of the artificial intelligence boom. You know Big Tech has been investing billions of dollars into it.
According to Next Move Strategy Consulting, the AI market – currently valued at about $100 billion – cold grow twenty-fold by 2030 to more than $2 trillion. That means you may want to strongly consider these top AI stocks. Get our free report, "Top 5 AI Stocks to Buy in 2024."
Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"
Sponsored
Regarding the SuperNova platform, the “Smallpox Vaccine for Cancer Treatment” was awarded by the US Patent and Trademark Office. This platform uses mesenchymal stem cells taken from adipose tissue that have been infected with the oncolytic vaccinia virus.
A cutting-edge tech startup, Calidi Biotherapeutics fortifies the body’s anti-cancer defenses. Strong allogeneic stem cells combined with oncolytic viral payloads are used in Calidi Biotherapeutics’ novel stem cell-based technologies to treat a variety of cancers, including solid tumors and high-grade gliomas.
Advancing Cancer Treatment with SuperNova Technology
The newly issued patent marks a critical milestone for Calidi Biotherapeutics as it prepares to advance CLD-201 into clinical settings. Specifically, it includes compositions combining a smallpox vaccine with various stem cell types, broadening previously allowed claims to encompass 21 different smallpox vaccine virus strains.
Calidi’s extensive research has demonstrated the SuperNova platform’s potential to protect the viral payload from the immune system, ensuring efficient delivery to tumor sites and enhancing the therapeutic efficacy of oncolytic viruses.
Future Prospects and Clinical Advancements
Calidi Biotherapeutics sees considerable potential in its SuperNova technology to address the critical need for effective treatments of solid tumors. Building on the initial success of its autologous adipose-derived stem cells loaded with vaccinia oncolytic viruses, Calidi plans to submit an Investigational New Drug (IND) application to initiate its first-in-human clinical trial of this off-the-shelf allogeneic therapy.
This effort aims to deepen the understanding of CLD-201’s safety and effectiveness in patients with advanced solid tumors, potentially transforming treatment options for this challenging condition.
